Climb Bio (CLYM) Net Equity Issued and Repurchased (2020 - 2024)
Climb Bio (CLYM) posted Net Equity Issued and Repurchased of $41000.0 for Q4 2024, down 98.19% on a QoQ basis from $2.3 million in Q3 2024, and down 85.76% year-over-year from $288000.0 in Q1 2024.
Climb Bio (CLYM) Net Equity Issued and Repurchased (2020 - 2024) Analysis & Trends
Climb Bio's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $41000.0 for Q4 2024.
- Quarterly Net Equity Issued and Repurchased fell 85.76% year-over-year to $41000.0 in Q4 2024, while the trailing twelve-month figure through Mar 2025 was $44.2 million (up 5067.13% YoY) and the FY2024 annual result came in at $11.0 million, up 1205.47% from the prior year.
- Net Equity Issued and Repurchased was $41000.0 for Q4 2024 at Climb Bio, down from $2.3 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $93.8 million in Q3 2021 and bottomed at -$93.8 million in Q4 2021.
- A 4-year average of $3.9 million and a median of $105000.0 in 2021 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased tumbled 2004.37% — and 2024, when it surged 174345.83%.
- Climb Bio's Net Equity Issued and Repurchased stood at $4.9 million in 2020, then tumbled by 2004.37% to -$93.8 million in 2021, then jumped by 100.31% to $288000.0 in 2023, then plunged by 85.76% to $41000.0 in 2024.
- Business Quant data shows CLYM's Net Equity Issued and Repurchased at $41000.0 in Q4 2024, $2.3 million in Q3 2024, and $41.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 141.90 Mn |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 41,000.00 |
| Dec 31, 2024 | 41,000.00 |
| Sep 30, 2024 | 2.27 Mn |
| Sep 30, 2024 | 2.27 Mn |
| Jun 30, 2024 | 41.87 Mn |
| Jun 30, 2024 | 41.87 Mn |
| Mar 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 15,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Dec 31, 2023 | 288,000.00 |
| Sep 30, 2023 | 528,000.00 |
| Sep 30, 2023 | 528,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2021 | -93.79 Mn |
| Dec 31, 2021 | -93.79 Mn |
| Sep 30, 2021 | 93.83 Mn |
| Sep 30, 2021 | 93.83 Mn |